First-in-Human Clinical Trial Evaluates Bispecific Antibody for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

 

Roswell Park Comprehensive Cancer Center is one of only five sites in the U.S. offering a first-in-human clinical trial to gauge the safety and anti-tumor activity of LTZ-301 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). A bispecific antibody, LTZ-301 is the first of its kind to target CD79b-positive B cells, which are highly expressed in NHL.

Led by Site Principal Investigator Francisco Hernandez-Ilizaliturri, MD, Professor of Oncology and Director of Lymphoma Research at Roswell Park, the non-randomized, phase 1 study (NCT07121946) offers a hopeful treatment option for this patient population, whose median overall survival is just six to 10 months. Patients must have undergone at least two previous systemic treatment regimens prior to relapse or disease resistance.

A myeloid cell engager, LTZ-301 recruits the immune system’s monocytes and macrophages to selectively attack and destroy CD79b-positive B cells. The trial will evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity.

“Preclinical studies of LTZ-301 have shown promising activity,” says Dr. Hernandez. “This may be a new treatment alternative for patients with refractory B-cell lymphoma.”

The clinical trial is sponsored by LTZ Therapeutics, Inc.

To refer a patient to this study, or to inquire about eligibility, please contact us by emailing physicianrelations@roswellpark.org or calling 716-845-RPMD (7763).